Episode Details
Back to EpisodesPhase 3 Results for Novel Sedation Tablet
Published 1 year, 5 months ago
Description
New phase 3 data is released for a non-opioid sedation tablet; the first patient is dosed in the phase 3 trial of EyePoint’s wet AMD candidate; and Outlook receives a reimbursement decision in the UK for its wet AMD treatment.
Learn more about your ad choices. Visit megaphone.fm/adchoices